Precision BioSciences vs Metagenomi Therapeutics
DTIL and MGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DTIL and MGX compare
Precision BioSciences is the larger company, worth 8.0 times as much as Metagenomi Therapeutics ($209M against $26.1M).
Metagenomi Therapeutics scores higher on the StockData Score (6 against 4 for Precision BioSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DTIL | MGX |
|---|---|---|
| Size and price | ||
| Market cap | $209M | $26.1M |
| Share price | $7.57 | $0.692 |
| Change, 1 year | 26.1% | −62.8% |
| Change, 5 years | −97.3% | – |
| Beta (5Y) | 1.27 | 1.28 |
| Employees | 68 | 119 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.6× | – |
| P/B | 4.0× | 0.3× (better) |
| FCF yield | −24.8% (better) | −320% |
| Fair value | $4.52 | – |
| Margin of safety | −67.5% | – |
| Growth | ||
| Revenue growth (TTM) | 6353% | – |
| Revenue growth, 5Y average | 7.1% | – |
| Profitability | ||
| Operating margin | −80.3% | – |
| Net margin | −85.6% | – |
| FCF margin | −115% | – |
| Return on equity | −113% | −69.4% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −28.6× | – |
| Current ratio | 10.47 (better) | 3.43 |
| Altman Z-score | −4.84 | −4.66 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 64.0% | 16.6% |
| Held by insiders | 3.0% | 10.4% |
| Insider net buying, 12 months | −$396K | −$9.7K (better) |
| Short interest, % of float | 7.8% | 3.9% |
Go deeper
- DTIL stock overview
- DTIL income statement
- DTIL valuation and score
- MGX stock overview
- MGX income statement
- MGX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.